174 related articles for article (PubMed ID: 23052253)
1. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
[TBL] [Abstract][Full Text] [Related]
2. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
Wang J; Cai Y; Yu W; Ren C; Spencer DM; Ittmann M
Cancer Res; 2008 Oct; 68(20):8516-24. PubMed ID: 18922926
[TBL] [Abstract][Full Text] [Related]
4. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
Shao L; Zhou Z; Cai Y; Castro P; Dakhov O; Shi P; Bai Y; Ji H; Shen W; Wang J
PLoS One; 2013; 8(3):e58391. PubMed ID: 23554889
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
7. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.
Hart M; Wach S; Nolte E; Szczyrba J; Menon R; Taubert H; Hartmann A; Stoehr R; Wieland W; Grässer FA; Wullich B
FEBS J; 2013 May; 280(9):2105-16. PubMed ID: 23480797
[TBL] [Abstract][Full Text] [Related]
8. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
10. ERG oncogene modulates prostaglandin signaling in prostate cancer cells.
Mohamed AA; Tan SH; Sun C; Shaheduzzaman S; Hu Y; Petrovics G; Chen Y; Sesterhenn IA; Li H; Sreenath T; McLeod DG; Dobi A; Srivastava S
Cancer Biol Ther; 2011 Feb; 11(4):410-7. PubMed ID: 21178489
[TBL] [Abstract][Full Text] [Related]
11. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.
Wang J; Cai Y; Shao LJ; Siddiqui J; Palanisamy N; Li R; Ren C; Ayala G; Ittmann M
Cancer Res; 2011 Feb; 71(4):1325-33. PubMed ID: 21169414
[TBL] [Abstract][Full Text] [Related]
12. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
[TBL] [Abstract][Full Text] [Related]
15. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
Zammarchi F; Boutsalis G; Cartegni L
PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
18. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
